Torrent Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Torrent Pharmaceuticals is navigating a transformative phase following its acquisition of JB Chemicals, which is expected to yield significant cost synergies and enhance its competitive position in the Indian pharmaceutical market. Management's focus on integrating operations and optimizing its product portfolio is crucial for driving revenue growth, particularly in chronic therapies. Despite facing short-term supply chain disruptions and margin pressures, the company's strategic initiatives, including the successful launch of semaglutide, position it well for future growth. Vista's financial outlook reflects an expectation of accelerating revenue growth, although margins may remain under pressure due to integration costs and pricing challenges in the US market. The favorable currency dynamics and strong domestic demand provide additional support for revenue stability. Over the next 12-24 months, key opportunities include leveraging the expanded chronic therapy portfolio and enhancing operational efficiencies, while watchpoints include execution risks during integration and potential regulatory challenges. Overall, while the long-term outlook remains positive, the stock's premium valuation and near-term headwinds warrant a cautious approach
Why We Like This Stock
- Accelerated realization of cost synergies from the JB Chemicals acquisition is expected to enhance margins over time
- Strong domestic demand and successful product launches, particularly in chronic therapies, support revenue growth
- Management's disciplined approach to integration and operational efficiency positions the company for long-term success
Things To Watch Out For
- Short-term supply chain disruptions and integration-related challenges may impact revenue and margins
- Pricing pressures in the US market could hinder revenue growth and profitability
- The stock trades at a premium valuation, which may limit upside potential amid current market uncertainties
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 10,728 | 11,516 | 13,980 | 17,472 | 21,053 |
| Profit Before Tax (Cr.) | 2,246 | 2,679 | 2,961 | 3,078 | 4,012 |
| PBT Margin | 20.9% | 23.3% | 21.2% | 17.6% | 19.1% |
| Net Profit (Cr.) | 1,815 | 2,058 | 2,091 | 2,160 | 2,815 |
| Earnings Per Share | 53.6 | 60.8 | 61.8 | 63.8 | 83.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| JPMorgan | ▲ Buy | 5,950 | 03-Aug-2026 |
| HSBC | ▲ Buy | 5,375 | 31-Jul-2026 |
| ICICI Securities | ► Hold | 4,925 | 31-Jul-2026 |
| Macguire | ▲ Outperform | 5,000 | 31-Jul-2026 |
| Morgan Stanley | ▲ Overweight | 5,623 | 31-Jul-2026 |
| Motilal Oswal | ► Neutral | 4,730 | 31-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 5,500 | 31-Jul-2026 |
| HDFC Securities | ► Add | 5,270 | 30-Jul-2026 |
| BPWealth | ▲ Buy | nan | 25-May-2026 |
| Jeffries | ▲ Buy | 5,350 | 25-May-2026 |
| Elara Capital | ► Accumulate | 4,351 | 23-Apr-2026 |
Company Overview
Show Company Profile
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.